Select Page

TG Therapeutics Inc Class Action Lawsuit TGTX | Deadline September 16, 2022

TG Therapeutics Inc Class Action Lawsuit
(TGTX Lawsuit)

The Gross Law Firm notifies investors that a class action (TG Therapeutics Inc Class Action Lawsuit) has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of TG Therapeutics, Inc. (TGTX) who purchased shares between January 15, 2020 and May 31, 2022.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:

(i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company’s therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until September 16, 2022 to request that the court appoint them lead plaintiff.

TG Therapeutics Inc Class Action Lawsuit

The deadline to submit a lead plaintiff motion in a securities class action lawsuit that has been brought on behalf of investors who bought or otherwise acquired securities of TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, inclusive (the “Class Period”) has passed. Bernstein Liebhard LLP, a nationally renowned investor rights law firm, reminds investors of this deadline. The Securities Exchange Act of 1934 is allegedly being violated, and the action was brought in the United States District Court for the Southern District of New York.

TG Therapeutics Inc Class Action

Please visit TG Therapeutics, Inc. if you purchased TG Therapeutics securities and/or would like to learn more about your rights and available choices. Contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to join a shareholder class action lawsuit.
Over 3.5 billion dollars have been recovered for clients by Bernstein Liebhard LLP since 1993. Some of the biggest public and private pension funds in the nation have hired the Firm to manage their assets and pursue lawsuits on their behalf in addition to defending individual clients. The Firm has been featured in The Legal 500 for ten consecutive years and has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times as a consequence of its success in the litigation of hundreds of lawsuits and class actions.

TG Therapeutics Inc Lawsuit

There has already been a class action complaint filed. You can study a copy of the complaint and sign the certification form, or you can call Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 to speak with Peretz Bronstein, Esq., or Yael Nathanson, his law clerk and client relations manager. You have until September 16, 2022, if you experienced a loss in TG Therapeutics, to ask the court to designate you as lead plaintiff. You are not required to act as the main plaintiff in order to share in any recovery.

TGTX Class Action Lawsuit

The focus of TG Therapeutics, a biopharmaceutical firm in the commercial stage, is on the acquisition, development, and commercialization of cutting-edge therapies for autoimmune disorders and B-cell malignancies. The Company’s therapeutic product candidates include Umbralisib, or UKONIQ, an oral PI3K-delta and CK1-epsilon inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma, as well as Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia

TGTX Class Action

There has already been a class action complaint filed. You can study a copy of the complaint and sign the certification form, or you can call Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 to speak with Peretz Bronstein, Esq., or Yael Nathanson, his law clerk and client relations manager. You have until September 16, 2022, if you experienced a loss in TG Therapeutics, to ask the court to designate you as lead plaintiff. You are not required to act as the main plaintiff in order to share in any recovery.

TGTX Lawsuit – TGTX stock

At the beginning of the class period, the share price of TG Therapeutics was $11.21, and by the end of July 2015, it had risen to $18.68. After that, though, it started to fall gradually, finishing 2015 at $11.93. Thanks in part to the information regarding the challenges of the GENUINE study, that decline persisted for the majority of 2016. When the GENUINE announcement was made on October 7, 2016, the stock had dropped to $8.25 from its recent high of $8.64 per share. The cost was merely $6.85 the following day, and it has been progressively declining ever since.

To receive more information, please fill out the form.

TG Therapeutics, Inc. Class Action Lawsuit
TG Therapeutics, Inc. Lawsuit
TGTX Class Action Lawsuit
TGTX Lawsuit
TG Therapeutics, Inc. (TGTX) Class Action Lawsuit
TG Therapeutics Inc Class Action Lawsuit,
TG Therapeutics Inc Class Action,
TG Therapeutics Inc Lawsuit,
TGTX Class Action Lawsuit,
TGTX Class Action,
TGTX Lawsuit,
TGTX Stock